active
ACTIVE SINCE: 2021

Project inSight

Together with the Global Fund, Johnson & Johnson collaborated on a program in Indonesia called Project inSight, launched in 2021, which aimed to further understand challenges and barriers in TB diagnosis and catalyze solutions to improve efforts to identify, engage and support people diagnosed with DR-TB.
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Intergovernmental Organizations and Multilaterals 1
Objectives

The initiative was aimed at supporting efforts in Indonesia to further understand challenges and barriers in TB diagnosis and catalyze solutions to improve efforts to identify, engage and support people diagnosed with DR-TB.

What are the health needs and challenges?

Even before the emergence of COVID-19, less than half of the approximately 500,000 new cases of DR-TB each year were properly diagnosed. By collaborating with national governments, not-for-profit organizations and other members of the private sector, Johnson & Johnson is helping to support efforts to identify the “missing” people with TB who have yet to be diagnosed, and therefore treated.

Collaboration activities and how they address needs and challenges

Project inSight was a collaboration between Johnson & Johnson and the Global Fund in Indonesia that improved understanding of why it can be difficult to identify people with DR-TB. By combining the Global Fund’s scale and reach and Johnson & Johnson’s unique expertise in consumer and patient insights, new strategies can be devised to amplify efforts to identify, engage and support people diagnosed with DR-TB, particularly in the context of the COVID-19 pandemic.

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.3: Communicable diseases and NTDs
  2. 3.8: Achieve universal health coverage
SDG 17: Partnerships for the goals 
Partner organizations
Intergovernmental Organizations and Multilaterals

Global Fund to Fight AIDS, Tuberculosis and Malaria

Additional information

FURTHER READING